1)Blumberg BS, Alter HJ, Visnich S:A “new” antigen in leukemia sera. JAMA 191:541-546,1965
2)Chan HL, Thompson A, Martinot-Peignoux M, et al:Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report. J Hepatol 55:1121-1131,2011
3)Tanaka E, Matsumoto A, Yoshizawa K, et al:Hepatitis B core-related antigen assay is useful for monitoring the antiviral effects of nucleoside analogue therapy. Intervirology 51(Suppl 1):3-6,2008
4)Fattovich G, Bortolotti F, Donato F:Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 48:335-352,2008
5)Ganem D, Prince AM:Hepatitis B virus infection--natural history and clinical consequences. N Engl J Med 350:1118-1129,2004
6)McMahon BJ:Natural history of chronic hepatitis B. Clin Liver Dis 14:381-396,2010
7)Ito K, Yotsuyanagi H, Sugiyama M, et al:Geographic distribution and characteristics of genotype A hepatitis B virus infection in acute and chronic hepatitis B patients in Japan. J Gastroenterol Hepatol, 2015, in press
8)朝比奈靖浩,泉並木,桶谷眞:B型肝炎治療ガイドライン(第1.1版).肝臓 54:402-472,2013
9) 難治性の肝・胆道疾患に関する調査研究班,肝硬変を含めたウイルス性肝疾患の治療の標準化に関する研究班:免疫抑制・化学療法により発症するB型肝炎対策ガイドライン(改訂版),2011(http://www.ryumachi-jp.com/info/news110926_gl.pdf)
10)Oketani M, Ido A, Uto H, et al:Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy. Hepatol Res 42:627-636,2012
11)Umemura T, Tanaka E, Kiyosawa K, et al:Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan. Clin Infect Dis 47:e52-e56,2008
12)日本肝臓学会肝炎診療ガイドライン作成委員会(編):B型肝炎治療ガイドライン(第2.1版),2015(https://www.jsh.or.jp/files/uploads/HBV_GL_ver2.1_May11.pdf)